Community Trust & Investment Co. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 761.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,555 shares of the company’s stock after purchasing an additional 11,098 shares during the period. Community Trust & Investment Co.’s holdings in Eli Lilly and Company were worth $11,123,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of LLY. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter valued at $32,000. LGT Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $36,000. Cedar Mountain Advisors LLC boosted its holdings in Eli Lilly and Company by 53.3% during the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after buying an additional 16 shares in the last quarter. Morton Brown Family Wealth LLC boosted its holdings in Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares in the last quarter. Finally, Unique Wealth Strategies LLC acquired a new position in Eli Lilly and Company during the second quarter worth about $45,000. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Trading Up 0.3 %
NYSE LLY opened at $909.15 on Wednesday. The company has a market cap of $864.06 billion, a P/E ratio of 133.90, a P/E/G ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company has a 50-day moving average of $921.67 and a 200-day moving average of $860.45.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Bank of America boosted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Citigroup started coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,002.24.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- UL Solutions Stock Breakout Imminent – Is Now the Time to Buy?
- What Are the U.K. Market Holidays? How to Invest and Trade
- GE Aerospace Margin Widens: Is It Time to Buy Dip?
- 3 Warren Buffett Stocks to Buy Now
- Rambus Stock Poised for Growth – Will the AI Boom Deliver?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.